MBio Diagnostics, Inc. Announces Sue Sutton-Jones Joins as VP of Regulatory
Affairs and Quality Assurance
BOULDER, CO -- (Marketwired) -- 04/09/13 -- MBio Diagnostics, Inc.
announced today that it has expanded its leadership team with the
addition of Sue Sutton-Jones as Vice President of Regulatory Affairs
and Quality Assurance. Ms. Sutton-Jones comes to MBio from ConMed
Livatec, a global leader in the fields of arthroscopy, endoscopic
medical video systems and powered surgical instruments. Prior to
this, Sue was with OraSure Technologies, Inc., where she led the
regulatory efforts for multiple products, including rapid tests for
HIV and hepatitis C, and was responsible for the initiative that
resulted in obtaining US FDA approval on the Premarket Approval
Application (PMA) for the first over-the-counter HIV rapid test. Ms.
Sutton-Jones is experienced in building high-performance regulatory
and quality teams with international scope and impact.
Commenting on Sue joining MBio, Christopher Myatt, CEO and Founder,
noted, "We are pleased to have Sue join the MBio team. She brings a
wealth of experience to our mission to increase access to quality
healthcare through innovative and low cost point of care
MBio Diagnostics, Inc. (www.mbiodx.com) is a privately held
diagnostics and life sciences company based in Boulder, CO. MBio
Diagnostics is increasing access to quality healthcare by delivering
innovative and low cost point-of-care (POC) diagnostics. The MBio
System is initially being commercialized to manage the treatment of
HIV patients from a single drop of blood. The MBio elegant detection
system is being developed for a broad menu of applications including
multiplex assays and cellular analysis.
For more information visit MBio at www.mbiodx.com or contact:
Christopher Myatt, Ph.D.
MBio Diagnostics, Inc.
Press spacebar to pause and continue. Press esc to stop.